Founded in 2005, True Ventures is a Silicon Valley-based venture capital firm that invests in early-stage technology startups. With more than $3.8 billion under management, True provides seed and Series A financing to entrepreneurs in some of today's growing markets.  With more than 40 team members including special advisors, operations professionals, and founders-turned-investors, True represents one of the largest and most experienced teams dedicated to the ecosystem.  The True team believes creativity flourishes when founders are supported fully and empowered to pursue brave ideas. To that end, the True Platform offers programs that inspire professional and personal growth. To date, True has helped more than 350 companies launch and scale their businesses, creating over 85,000 jobs worldwide.  True was awarded Venture Firm of the Year by the National Venture Capital Association in 2018. To learn more, visit www.trueventures.com.

True Ventures

415 Ventures operates as a venture capital firm. Our  first investment is a social media-networking site called ViewersRepublic.com, which uses user-generated contents, i.e. videos, photos, blogs, and music to introduce and connect one member to another.  ViewersRepublic.com also serves as an alternative to iTunes and Amazon as a place to sell music. What we have over the other guys is that we do not take commissions out of the revenue the artists/bands make selling through us. We charge a one-time fee for setting up the album, and $20 a month for selling through us. In addition, we take the a lot of the stress out of out trying to get their music heard for indies because we provide a radio function that they can automatically add their music to, which is available for free streaming by ALL visitors. We also provide this service to major labels worldwide.

415 Ventures

Founded in 2014 by Owen Van Natta and Grace Stanat. 415 provides seed funding for and advises (primarily early stage) companies. 415 assists in the areas of strategy, funding, deals/partnerships, social, e- and m-commerce, operations, user acquisition/engagement, culture and growth.

Civilization Ventures invests in visionary founders that are leading the future of health tech and biology-driven innovation. We aim to be the first check and lead investor in highly disruptive companies across digital health, synthetic biology, diagnostics, 3D (bio) printing, and AI/ software-enabled health tech. Our team comprises serial entrepreneurs and industry thought leaders who work tirelessly to help each of our portfolio companies succeed.

Civilization Ventures

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins the later rounds of HAX and IndieBio graduates.  HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

SOSV

IndieBio is the world’s first accelerator devoted to startups using biology to solve the world's largest problems. IndieBio is an SOSV program. SOSV is a global venture capital firm that operates startup accelerator investment programs. At the close of 2020, SOSV had more than 1,000 portfolio companies and $855 million in assets under management.

IndieBio

Cantos is a pre-seed venture capital firm with $90M under management that invests in founders audacious enough to believe they can change the world.

Cantos

Plug and Play is a seed and early-stage investor focused on great teams leading emerging growth companies.  Plug and Play runs 12 industry-specific accelerator programs twice a year, that acts as a platform for major corporations and high quality startups to connect and collaborate.  Located in the heart of Silicon Valley, Plug and Play participates in Seed, Angel and Series A funding where they often co-invest with their strategic partners. Through years of experience and as part of their network, Plug and Play has put together a world-class network of serial entrepreneurs, strategic investors, and industry leaders who actively assist the firm with its successful and growing investment portfolio.  SEED ROUND. Plug and Play participates in seed round investing through a program called Startup Camp. Startup Camp is a 10-week program based in Silicon Valley for top-notch entrepreneurs to work intensively on building out their business model. Select startups will refine their business models and prototypes with help from a combination of structured workshops, speaker series and mentorship sessions, as well as active coaching from their investment team. At the culmination of Startup Camp, founders will have crystalized their business plans and pitched their company to the venture capital community at EXPO Demo Day.''  ANGEL ROUND Plug and Play makes angel round investments throughout the year, sourced from their monthly Plug and Play Angels (PAPA) sessions. They are partnered with local angel investors in Silicon Valley who participate in PAPA to find the most promising startups and best new technologies.  SERIES A. Series A typical Series A round is in the range of $2 million to $10 million, and is intended to provide operating capital for the company for six months to two years. This round capitalizes the company as it develops its products, performs initial marketing and branding, acquires talent, and conducts other early-stage business operations. It is in this stage that Plug and Play will co-invest with over 180 venture capital partners.  Plug and Play has helped grow market leaders such as PayPal, Danger, Google, DropBox, LendingClub, Zoosk, SoundHound, CreditSesame, Skytree, and has over 400 more early-stage startups in its portfolio.

Plug and Play

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technology.

Khosla Ventures

Celesta Capital is a venture capital firm that invests in entrepreneurs and disruptive technology companies. Their management team and investment professionals leverage over 400 years of accumulated investment and operational experience and bring to their portfolio companies a deep and unmatched network of value-added strategic relationships.  Celesta Capital invests globally and has offices in California, Israel, India, and China

Celesta Capital

Avidity Partners is an investment management firm that offers financial services.

Avidity Partners

We are opportunistic investors with +25 years of dedication to the VC and tech community. Founded by second-generation venture capitalist Chris Lucas, our firm thrives on evaluating multi-stage companies with visionary founders poised to transform their markets. Our passionate group of partners bring their successful track records as seasoned investors, serial entrepreneurs, and operators to BDV. Together, we deliver access to leading and top-tier investment opportunities through our established +35 years of network, supporting extraordinary founders every step of the way.

Black Diamond Ventures

Lucas Venture Group is a second generation venture capital firm focused on investments of $500,000-$5,000,000  Our focus spans robotics, networking, software analytics/big data, and trans formative autonomous machines. LVG was founded by second-generation venture capitalist Donald A. Lucas, who grew up in an environment steeped in the entrepreneurial spirit in Silicon Valley. He has spent his entire professional career focused on investing in private companies, working with entrepreneurs and their management teams, leveraging his vast network to create value throughout all stages of investments.

Lucas Venture Group

Prellis Biologics

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier. The company was founded in 2016 and is based in San Francisco, California.

Prellis Biologics is a biotherapeutics company that leverages its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. Its flagship product is EXIS (Externalized Human Immune System), a platform that precisely reproduces the human immune response through the creation of lymph node organoids (LNOs). By challenging these LNOs with various target antigens, Prellis can exploit fully-human immune responses for applications such as antibody discovery, immunogenicity assessment, and tumor-immune models.

Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development

Prellis Biologics Announces Collaboration with Sanofi

Prellis Biologics hires new CEO, raises $35M towards 3D bioprinted lymph node R&D

Bioprinting Capabilities and Futures

How a pandemic pivoted Prellis from laser-printed organs to in vitro immune systems

With $35M Bioprinting Investment Prellis Biologics Takes on New CEO - 3DPrint.com

Interview with Gavan Wilhite, Software Design for Bioprinting Prellis Biologics

Newborns, Warriors, Unicorns, Winners: Commercialization of Healthcare 3D Printing In 2020

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

Scientist/Sr.Scientist-Immunology job with Prellis Biologics, Inc. | 2910680

Bristol-Myers Squibb

Prellis Biologics has partnered with Bristol Myers Squibb for drug discovery using its EXIS platform. The collaboration aims to generate high affinity human antibodies targeting specific proteins

Prellis Biologics is a biotherapeutics company that leverages its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. Its flagship product is EXIS (Externalized Human Immune System), a platform that precisely reproduces the human immune response through the creation of lymph node organoids (LNOs). By challenging these LNOs with various target antigens, Prellis can exploit fully-human immune responses for applications such as antibody discovery, immunogenicity assessment, and tumor-immune models.
The company's industry-leading two-photon holographic technology supports 3D printing of large, complex tissue co-culture systems like LNOs. With EXIS, Prellis can discover fully human antibodies with broad genetic diversity in as little as three to four weeks, significantly accelerating the antibody discovery process compared to conventional methods. In March 2022, Prellis announced a collaboration with Sanofi focused on generating human antibodies for a target of interest, with Sanofi receiving an exclusive option to license and commercialize the resulting antibodies.
In August 2022, Prellis raised USD 35 million in Series C funding to expand the EXIS platform, bringing its total funding to USD 64.5 million. The company also appointed Michael Nohaile as CEO, with founder Melanie Matheu transitioning to the role of Chief Technology Officer. Earlier in 2022, Prellis entered into a collaboration and licensing option agreement with Bristol Myers Squibb.

3D Bioprinting Solutions is a Russian biotechnology research laboratory focused on developing and commercializing bioprinting technologies. The company was founded by INVITRO, the largest private medical company in Russia, and officially opened its 3D Bioprinting Solutions laboratory in September 2013. Its core activities involve the development and production of bioprinters, bioinks, and biofabrication technologies for regenerative medicine and drug discovery applications.
One of the company's key products is the FABION bioprinter, capable of bioprinting without the need for organic or artificial scaffolds using a proprietary nanotechnology approach. In 2016, 3D Bioprinting Solutions launched the FABION 2, an advanced bioprinter that can print complex structures using tissue spheroids and a wide range of hydrogels with different polymerization mechanisms. The FABION two features a unique laser positioning system with an accuracy of five micrometers, enabling the printing of highly intricate structures.
In 2018, the company delivered its Organ.Aut magnetic 3D bioprinter to the International Space Station (ISS) for conducting experiments in microgravity conditions. The Organ.Aut successfully bioprinted a mouse's thyroid gland in space in December 2018, marking the first instance of living tissue being printed in outer space. In August 2019, the company bioprinted bone tissue aboard the ISS using the Organ.Aut.
3D Bioprinting Solutions has actively pursued collaborations with research institutions and commercial entities worldwide. In April 2019, the company announced plans to collaborate with laboratories from the US and Israel to deliver muscular tissue biomaterials to the ISS for bioprinting experiments using the Organ.Aut bioprinter.

3D Bioprinting Solutions

A.D.A.M. Bioprinting is a company developing an on-demand 3D bioprinting platform for manufacturing personalized implants. Their core technology, a Medical Device Production System, enables medical professionals to complete the entire process of 3D modeling, printing, and sterilization to create customized implants ready for implantation.
The company's initial focus is on producing orthopaedic bone implants for cranial, maxillofacial, general trauma, and orthopaedic oncology surgeries. However, A.D.A.M. Bioprinting plans to expand its offerings to include printed soft tissues in the future.
Founded in 2018, A.D.A.M. Bioprinting has its roots in Ukrainian aerospace and biotech engineering. The company operates with a research and development office in Ukraine, while its US-based entity holds intellectual property and handles business development and marketing functions.
In May 2022, A.D.A.M. Bioprinting was accepted into Elementa Labs, the virtual incubator program of the Mount Sinai Health System in New York. This program aims to optimize, expand, and advance the company's core technology platform, potentially leading to its commercialization in the US market.

A.D.A.M.

Advanced BioMatrix, a San Diego-based biotechnology company, develops advanced biomaterials and reagents for 3D cell culture applications, including cell cultivation, cell assays, bioprinting, and cell proliferation. The company's products have been utilized in groundbreaking research for drug development and 3D bioprinted tissue models, with over 5,000 citations in scientific publications as of September 2021. Advanced BioMatrix's offerings include hydrogels that mimic the extracellular matrix, facilitating cellular attachment, survival, and compatibility with various tissue types.
In September 2021, Advanced BioMatrix was acquired by BICO Group AB, a Swedish bioconvergence company focused on enhancing biology research, for approximately USD 15 million. Following the acquisition, Advanced BioMatrix became a subsidiary of CELLINK Bioprinting, operating under the BICO Group. The company generated approximately USD 3 million in revenue with an adjusted EBITDA margin of around 50% in its latest fiscal year prior to the acquisition.
Key customers and partnerships
Advanced BioMatrix has established collaborations with research institutes, pharmaceutical companies, and life science organizations worldwide. In June 2022, the company expanded its existing partnership with Lineage Cell Therapeutics for Lineage's HyStem cell/drug delivery technology, broadening its focus on manufacturing and supplying research-grade HyStem to the research community and developing clinical/commercial-grade material for Lineage's customers.
In August 2023, Advanced BioMatrix signed a distribution agreement with InSphero AG, a pioneer in 3D cell culture and organ-on-chip technology, to make InSphero's patented Akura Plate Technology available to researchers in the US market. This collaboration aims to expand the application range for scientists and drug developers by combining Advanced BioMatrix's biomaterials with InSphero's Akura Plates for scaffold-based organoid and spheroid cultures.

Advanced Biomatrix

Advanced Solutions Life Sciences, a wholly-owned subsidiary of Advanced Solutions, Inc., is a global leader in 3D biofabrication, headquartered in Louisville, Kentucky. The company pioneered the BioAssemblyBot, the world's first 6-axis robotic human tissue printer capable of systematically reproducing organoids. Their patented 3D printed blood vessel technology, derived from human fat tissue, empowers customers to advance the science of 3D organ printing. Advanced Solutions Life Sciences offers expertise in regenerative medicine, bioinks, 3D tissue assays for drug discovery and testing, 3D tissue modeling, and 3D printing services.
In May 2018, the company expanded its operations by opening a second biofabrication facility and laboratory in Manchester, New Hampshire. This strategic expansion aimed to contribute to curative organ printing solutions and establish the company as a prominent corporate citizen in Manchester.
In January 2023, Advanced Solutions Life Sciences partnered with Molecular Devices, a bioscience company, to develop 3D biology automation solutions. They jointly developed the BioAssemblyBot 400 (BAB 400) for Drug Discovery, integrating Advanced Solutions' bioprinting platform with Molecular Devices' ImageXpress Cellular Imaging System. This automated platform enables consistent, large-scale production of organoid models, enhancing drug discovery research.

Advanced Solutions Life Sciences

Allegro 3D is a bioprinting company specializing in high-throughput and high-precision 3D printing technology for fabricating tissue models at an industrial scale. The company was acquired by BICO, a Swedish bioconvergence company, in May 2022 for an upfront enterprise value of USD 6 million. Allegro 3D's patented light-based digital light processing (DLP) bioprinting technology enables direct printing into multi-well plates, allowing customers to significantly increase their output of biofabricated constructs for applications in regenerative medicine and drug discovery workflows. The company's flagship product, the STEMAKER Model D, utilizes extrusion-based bioprinting to produce bio/organic parts using liquid feedstock. As of 2022, Allegro 3D was expected to generate approximately USD 1 million in revenue with positive EBITDA margins. The acquisition complements BICO's existing portfolio of bioprinters and strengthens its position as a global leader in providing bioprinting solutions.

Allegro 3D

Developing and selling bioprinter devices that can be used by hospitals, research institutes, and other organizations seeking to print biological substitutes and materials.

Companies that use propietary or third-party printers to produce and sell bioprinted tissues, including impants, organ replacement, and other types of tissues.

Companies that are developing materials and bioinks, that can be used in bioprinting devices. This includes material technologies and nanofibers.

Developing software solutions and applications for designing and managing the bioprinting production process.

3D printing enables bioprinting devices, which rely on a similar design and operating model

Startups in this hub are able to customize the bioprinted models to suit each patient

AI/ML is used in the design and optimization of 3D models that can be bioprinted

Prellis Biologics

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless